International Cancer Conference Journal

, Volume 6, Issue 2, pp 55–59 | Cite as

A case of premenopausal breast cancer with symptomatic cerebellar metastasis successfully treated by systemic endocrine therapy alone: relationship to biological features

  • Yoshitaka Fujiki
  • Yutaka Yamamoto
  • Mutsuko Yamamoto-Ibusuki
  • Lisa Goto
  • Takashi Takeshita
  • Hirotaka Iwase
Case report
  • 62 Downloads

Abstract

We report a case of premenopausal breast cancer with symptomatic cerebellar metastasis successfully treated by systemic endocrine therapy alone. The patient developed dysarthria, headache, lightheadedness and became difficult to write gradually. The cerebellar tumor was detected by computed tomography (CT) and was suspected hemangioma or hemangioblastoma. The tumor was resected and histologically diagnosed as poorly differentiated adenocarcinoma or squamous cell carcinoma. A whole body CT scan revealed a right thyroid tumor and left breast tumor. Core needle biopsy of the breast tumor histologically diagnosed the tumor as estrogen receptor positive, progesterone receptor positive, human epidermal growth factor receptor-2 negative, and Ki-67 labeling index 5%. After these examinations, histologically, the resected cerebellar tumor showed the same subtype as the breast tumor, so the final diagnosis was metastatic breast cancer with cerebellar metastasis. The patient subsequently received radiotherapy with the CyberKnife and endocrine therapy without resection of the thyroid tumor. Her medical condition has maintained a good response and stable disease for 7.5 years after the start of treatment. Analysis of four ESR1 mutations showed no mutations in the cerebellar metastatic lesion and breast cancer tissue. Our findings show that these tumors have high hormone responsiveness.

Keywords

Breast cancer Brain metastasis ESR1 

Notes

Compliance with ethical standards

Conflict of interest

Yutaka Yamamoto received lecture fees from Chugai Pharmaceutical Co., Ltd. Hirotaka Iwase received lecture fees and research funding from AstraZeneca and Takeda Co., Ltd. Other authors have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Wroński M, Arbit E, McCormick B (1997) Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 80(9):1746–1754CrossRefPubMedGoogle Scholar
  2. 2.
    Ramakrishna N, Temin S, Chandarlapaty S et al (2014) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(19):2100–2108CrossRefPubMedGoogle Scholar
  3. 3.
    Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2015) Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res 166(6):540–553CrossRefPubMedGoogle Scholar
  4. 4.
    Boogerd W, Vos VW, Hart AA, Baris G (1993) Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 15(2):165–174CrossRefPubMedGoogle Scholar
  5. 5.
    Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617CrossRefPubMedGoogle Scholar
  6. 6.
    Hortobagyi GN (1998) Treatment of breast cancer. New Engl J Med 339:974–984CrossRefPubMedGoogle Scholar
  7. 7.
    Iwase H, Yamamoto Y (2015) Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Int J Clin Oncol 20(2):253–261CrossRefPubMedGoogle Scholar
  8. 8.
    Klijn JG, Blamey RW, Boccardo F et al (2001) Combined hormone agents Trialists’Group and the European organization for research and treatment of cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four randomized trials. J Clin Oncol 19(2):343–353CrossRefPubMedGoogle Scholar
  9. 9.
    Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer:a randomized study. J Natl Cancer Inst 92(11):903–911CrossRefPubMedGoogle Scholar
  10. 10.
    Niikura N, Hayashi N, Masuda N et al (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103–112CrossRefPubMedGoogle Scholar
  11. 11.
    Michelle E, Dan H, Penny K et al (2008) Brain metastasis in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 88:359–365CrossRefGoogle Scholar
  12. 12.
    Altundag K, Bondy ML, Mirza NQ et al (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110(12):2640–2647CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2016

Authors and Affiliations

  • Yoshitaka Fujiki
    • 1
  • Yutaka Yamamoto
    • 1
  • Mutsuko Yamamoto-Ibusuki
    • 2
  • Lisa Goto
    • 1
  • Takashi Takeshita
    • 1
  • Hirotaka Iwase
    • 1
  1. 1.Department of Breast and Endocrine SurgeryKumamoto University Graduate School of Medical SciencesKumamotoJapan
  2. 2.Department of Molecular-Targeting Therapy for Breast CancerKumamoto University HospitalKumamotoJapan

Personalised recommendations